Latest Articles
CCDC138 Overexpression Predicts Poor Prognosis and Highlights Ciliopathy-Linked Mechanisms in Uterine Corpus Endometrial Carcinoma - Frontiers
CCDC138 Overexpression Predicts Poor Prognosis and Highlights Ciliopathy-Linked Mechanisms in Uterine Corpus Endometrial Carcinoma Frontiers
Published: July 29, 2025, 9:59 a.m.
Endometrial Carcinoma in Kenya: Clinical and Biomarker Profiles of 123 Cases Seen at Two Tertiary Referral Centers Authors - Frontiers
Endometrial Carcinoma in Kenya: Clinical and Biomarker Profiles of 123 Cases Seen at Two Tertiary Referral Centers Authors Frontiers
Published: July 28, 2025, 10:48 p.m.
Clinical value of D-dimer combined with transvaginal ultrasonography in the postmenopausal population with endometrial carcinoma - Nature
Clinical value of D-dimer combined with transvaginal ultrasonography in the postmenopausal population with endometrial carcinoma Nature
Published: July 28, 2025, 2:21 p.m.
Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities - Nature
Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities Nature
Published: July 24, 2025, 1:07 p.m.
Analysis of postoperative prognosis of non-metastatic endometrial carcinoma under different recurrence patterns - Nature
Analysis of postoperative prognosis of non-metastatic endometrial carcinoma under different recurrence patterns Nature
Published: July 22, 2025, 8:14 a.m.
Triple Threat: Co-occurrence of Serous Borderline Ovarian Tumor, Endometrial Adenocarcinoma, and Low-Grade Appendiceal Mucinous Neoplasms With Pseudomyxoma Peritonei in a Single Patient - Cureus
Triple Threat: Co-occurrence of Serous Borderline Ovarian Tumor, Endometrial Adenocarcinoma, and Low-Grade Appendiceal Mucinous Neoplasms With Pseudomyxoma Peritonei in a Single Patient Cureus
Published: July 20, 2025, 7:43 a.m.
Parexel Supports GLP-1 Trials for Metabolic Disorders as Eisai Investigates Dual-Mechanism Therapy for Endometrial Carcinoma - geneonline.com
Parexel Supports GLP-1 Trials for Metabolic Disorders as Eisai Investigates Dual-Mechanism Therapy for Endometrial Carcinoma geneonline.com
Published: July 18, 2025, 11:05 a.m.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma - PharmExec
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma PharmExec
Published: July 18, 2025, 10:08 a.m.
Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma - PharmExec
Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma PharmExec
Published: July 17, 2025, 10:09 a.m.
Immunogenic Cell Death-Related Genes as Prognostic Biomarkers and Therapeutic Insights in Uterine Corpus Endometrial Carcinoma: An Integrative Bioinformatics Analysis - Frontiers
Immunogenic Cell Death-Related Genes as Prognostic Biomarkers and Therapeutic Insights in Uterine Corpus Endometrial Carcinoma: An Integrative Bioinformatics Analysis Frontiers
Published: July 14, 2025, 4:41 p.m.
Link copied to clipboard!